Soligenix Receives FDA Protocol Clearance of Pivotal Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients

PRINCETON N.J. May 3 2017 PRNewswire Soligenix Inc. Nasdaq SNGX Soligenix or the Company a latestage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need announced today t...